Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
Phase of Trial: Phase IV
Latest Information Update: 29 Apr 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 08 Apr 2015 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 08 Apr 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.